MAGELLAN LONGEVITY
HomeResearchStudy library › Lipoprotein(a) and Cardiovascular Disease
Study summary · General aging biology & healthspan

Does high lipoprotein(a) (Lp(a)) concentration causally increase the risk of ischemic cardiovascular disease, and does it represent an unmet medical need?

In one paragraph

Lipoprotein(a), a review (Clin Chem 2021, PMID 33236085) — high Lp(a) concentrations are present in 10%-20% of the population, affecting an estimated >1 billion individuals worldwide. The review highlights the need for randomized cardiovascular outcome trials to provide final evidence of causality and assess the clinical benefit of novel Lp(a) lowering therapies, indicating that current evidence, while strong, is not definitive for treatment decisions.

Source: Clin Chem 2021, PMID 33236085 ↗ · Research map · How Magellan grades evidence · evidence confidence: high

Clin Chem · 2021 · PMID 33236085 · DOI 10.1093/clinchem/hvaa247

Plain-English summary written and published by Magellan Longevity · medical review by Gabriel Radu, DO (physiatrist, NPI 1376861765). We summarize what the paper reported — we did not run this study.

The takeaway

High lipoprotein(a) levels are causally linked to increased cardiovascular disease risk, but more research is needed to confirm treatment benefits.

The question

Does high lipoprotein(a) (Lp(a)) concentration causally increase the risk of ischemic cardiovascular disease, and does it represent an unmet medical need?

What they tested

The review implicitly hypothesizes that high Lp(a) concentrations are causally linked to increased cardiovascular disease risk and may represent an unmet medical need requiring treatment.

How they did it

This is a narrative review summarizing evidence from mechanistic, observational, and large genetic epidemiologic studies regarding the causality of high Lp(a) concentrations in cardiovascular disease. It also discusses Lp(a) measurement methods and future treatment options.

What they found

Evidence from mechanistic, observational, and genetic studies supports a causal role of Lp(a) in the development of cardiovascular disease, including coronary heart disease, peripheral arterial disease, aortic valve stenosis, and likely ischemic stroke. High Lp(a) concentrations predict 2- to 3-fold increases in risk for myocardial infarction, peripheral arterial disease, and aortic valve stenosis. High Lp(a) concentrations are present in 10%-20% of the population, affecting an estimated >1 billion individuals worldwide.

Increased Risk of Cardiovascular Events with High Lipoprotein(a)
Values shown: Fold Increase in Risk
Myocardial Infarction2.5
Peripheral Arterial Disease2.5
Aortic Valve Stenosis2.5

High lipoprotein(a) concentrations predict 2- to 3-fold increases in risk for myocardial infarction, peripheral arterial disease, and aortic valve stenosis. The chart uses the midpoint value of 2.5 for illustration.

What it means

High lipoprotein(a) concentrations are causally linked to an increased risk of cardiovascular diseases such as myocardial infarction, peripheral arterial disease, and aortic valve stenosis. Standardized Lp(a) measurements are crucial, and randomized cardiovascular outcome trials are necessary to confirm causality and evaluate the clinical benefit of Lp(a)-lowering therapies.

Limitations

The review highlights the need for randomized cardiovascular outcome trials to provide final evidence of causality and assess the clinical benefit of novel Lp(a) lowering therapies, indicating that current evidence, while strong, is not definitive for treatment decisions.

“high lipoprotein(a) concentrations predict 2- to 3-fold increases in risk”— from the published abstract, Clin Chem 2021

The paper at a glance

TitleLipoprotein(a) and Cardiovascular Disease
JournalClin Chem
Year2021
PMID33236085 ↗
DOI10.1093/clinchem/hvaa247 ↗
TopicGeneral aging biology & healthspan

Read the source: PubMed record (authors, abstract, full citation) ↗ · Publisher via doi.org ↗

Where Magellan uses this paper

This citation sits behind the evidence grade on the pages below. Grades are set from the research and are independent of affiliate commissions.

Lp(a) Mail-In Test

Large meta-analyses, prospective cohorts, and Mendelian randomization studies establish elevated Lp(a) as a causal, independent risk factor for coronary heart disease, myocardial infarction, ischemic stroke, peripheral artery disease, and calcific aortic valve stenosis, with roughly one in five people carrying high…

Lp(a) Mail-In Test

Lipoprotein(a), or Lp(a), is a low-density lipoprotein (LDL)-like particle in which an…

Check price on Amazon ↗

Research describes the compound or intervention studied. It is not a claim about any specific product.

Cite this page

These citations point at this summary. To cite the original paper with its full author list, use the PubMed record or doi.org.

APA
Magellan Longevity. (2026). Does high lipoprotein(a) (Lp(a)) concentration causally increase the risk of ischemic cardiovascular disease, and does it represent an unmet medical need? [Plain-English summary of Clin Chem 2021, PMID 33236085, DOI 10.1093/clinchem/hvaa247]. Magellan Longevity. https://magellanlongevity.com/study/d33236085.html
BibTeX
@misc{magellan_d33236085, title = {Does high lipoprotein(a) (Lp(a)) concentration causally increase the risk of ischemic cardiovascular disease, and does it represent an unmet medical need?}, author = {{Magellan Longevity}}, year = {2026}, howpublished = {\url{https://magellanlongevity.com/study/d33236085.html}}, note = {Plain-English summary of PubMed PMID 33236085; DOI 10.1093/clinchem/hvaa247; Clin Chem 2021. Reviewed by Gabriel Radu, DO}, urldate = {2026-08-11} }
Permalink
https://magellanlongevity.com/study/d33236085.html

Related studies in the Magellan library

All 25 Magellan summaries on general aging biology & healthspan →

How this summary was made. Every section above restates what the published abstract of PMID 33236085 reports — the question, the design, the numbers, the authors’ own conclusion and their stated limitations. We do not add claims the paper did not make, and we keep negative and no-effect findings in. Magellan’s evidence grades are set from research like this and never from affiliate commissions.

Prefer the interactive version? Open this summary in the Magellan app → · Browse all 314 study summaries →

Educational information, not medical advice. This is a plain-English summary of published research; it is not a treatment recommendation and nothing here is intended to diagnose, treat, cure, or prevent any disease. Individual studies can be wrong, and a single paper rarely settles a question. Talk to your physician before acting on any research, especially if you are pregnant, nursing, or taking medication.